This brand name is authorized in Australia, New Zealand, Spain.
The drug REANDRON contains one active pharmaceutical ingredient (API):
1
|
UNII
H16A5VCT9C - TESTOSTERONE UNDECANOATE
|
|
Testosterone, secreted by the testes and its major metabolite dihydrotestosterone (DHT), is responsible for the development of the external and internal genital organs and for maintaining the secondary sexual characteristics (stimulating hair growth, deepening of the voice, development of the libido); for a general effect on protein anabolism; for development of skeletal muscle and body fat distribution; for a reduction in urinary nitrogen, sodium, potassium, chloride, phosphate and water excretion. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| G03BA03 | Testosterone | G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03B Androgens → G03BA 3-oxoandrosten (4) derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 10205D |
| ES | Centro de información online de medicamentos de la AEMPS | 66470 |
| NZ | Medicines and Medical Devices Safety Authority | 12832 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.